Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.
Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, Inamoto Y, Miyamura K, Sawa M, Murata M, Karasuno T, Taniguchi S, Nagafuji K, Atsuta Y, Suzuki R, Fukumoto M, Naoe T, Morishita Y; Nagoya Blood and Marrow Transplantation Group.
Kuwatsuka Y, et al. Among authors: yasuda t.
Cancer Sci. 2012 Sep;103(9):1688-94. doi: 10.1111/j.1349-7006.2012.02342.x. Epub 2012 Jul 16.
Cancer Sci. 2012.
PMID: 22631696
Free PMC article.
Clinical Trial.